Abstract 284TiP
Background
Landmark trials have established a survival benefit for novel hormonal agents (NHA) added to androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). Yet, there is a significant medical need to expand therapeutic options, especially for pts with high-risk mHSPC who experience poorer outcomes. Abemaciclib is an oral selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6) dosed on a continuous schedule and approved for the treatment of node-positive high-risk early-stage and advanced or metastatic HR+, HER2− breast cancer. Analogous to the estrogen receptor signaling pathway in breast cancer, there is evidence that the androgen receptor axis activates CDK4/6 to sustain prostate cancer cell proliferation, and upregulation of cyclin D1 is a potential mechanism of resistance to NHA therapy. In preclinical models, abemaciclib induces cell cycle arrest and inhibition of prostate tumor growth.
Trial design
CYCLONE 3 is a global, randomized, double-blind, placebo-controlled study evaluating the addition of abemaciclib to abiraterone+prednisone (AP) in pts with high-risk mHSPC. Approximately 900 pts with high-risk mHSPC defined by ≥4 bone metastases and/or visceral disease will be randomised in a 1:1 ratio to the AP + abemaciclib or AP + placebo arm. Up to 3 months of ADT prior to randomization is permitted; prior docetaxel for mHSPC is excluded. Pts who has not undergone orchiectomy will continue ADT. Stratification factors are de novo mHSPC and visceral metastases. Primary endpoint is investigator-assessed radiographic progression-free survival (rPFS). Key secondary endpoints include rPFS assessed by blinded independent central review, castration-resistant prostate cancer-free survival, overall survival, time to pain progression, safety and pharmacokinetics. Approximately 270 sites across 24 countries are participating, including in Asia. Updated from abstract previously presented at European Society for Medical Oncology (ESMO) 2022, FPN (Final Publication Number): 2189, Rana McKay et al. Reused with permission.
Clinical trial identification
NCT05288166.
Editorial acknowledgement
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
N. Matsubara: Other, Personal and Institutional, Advisory Role, Honoraria, Speakers’ bureau, Research funding: Janssen, MSD; Other, Personal and Institutional, Research Funding, Honoraria: Taiho; Other, Personal and Institutional, Advisory Role, Research funding: Bayer, Roche; Other, Personal and Institutional, Advisory Role, Speakers’ bureau: Sanofi; Other, Personal and Institutional, Speaker’s Bureau: AstraZeneca. N. Agarwal: Other, Personal and Institutional, Advisory Role: Eli Lilly & Company, Janssen, Pfizer, Bayer, Amgen, Novartis, Bristol Myers Squibb, Astellas Pharma, AstraZeneca, ORIC Pharmaceuticals, Nektar, Pharmacyclics, Foundation Medicine, Eisai, AVEO; Other, Personal, Advisory Role: Calithera Biosciences, MEI Pharma, Gilead Sciences, Takeda. M.R. Smith: Other, Personal and Institutional, Advisory Role, Honoraria, Research Funding: Astellas Pharma, Bayer, Pfizer, Janssen, Lilly; Other, Personal and Institutional, Research Funding: Arvinas. R.R. McKay: Financial Interests, Personal, Research Funding, Consulting or Advisory Role: Bayer, Pfizer, Tempus; Financial Interests, Personal, Advisory Role: Astellas Medivation, AstraZeneca, Aveo, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novartis, Sanofi. T. Todenhöfer: Financial Interests, Personal, Advisory Role: Eli Lilly and Company, Janssen, Pfizer, Bayer, Novartis, Amgen, Bristol Myers Squibb, Astellas Pharma, AstraZeneca, Roche, Ipsen, Basilea. J.M. Piulats Rodriguez: Financial Interests, Personal, Advisory Role: Pfizer, Janssen, Bristol Myers Squibb, Merck, Roche, AstraZeneca, Astellas Pharma, Clovis Oncology, VCN Biosciences, Incyte, EMD Serono, BeiGene. K.L. Chung, D. Heirich, S. Sherwood, C. Schaverien, N. Fasnacht, A. Lithio, K. Nacerddine: Financial Interests, Personal, Other, Employee and Shareholder: Eli Lilly and Company. All other authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract